medicinal products with regard to vCJD risk», November 2003, EMEA/CPMP/BWP/5136/03. c) CHMP Position Statement «Creutzfeldt-Jakob disease and plasma-derived and urine-derived
Derived Medicinal Products with regard to vCJD risk», October 2004, EMEA/CPMP/BWP/5136/03.